Insight

Hung Trinh: Superior Tumor Immunotherapy

Hung Trinh/LinkedIn

Jul 15, 2025, 08:13

Hung Trinh: Superior Tumor Immunotherapy

Hung Trinh, CMC/MFG Consultant and Managing Director at Vertex Biopharm Consulting, shared a post on LinkedIn:

“α-GalCer-LNP ehanced mRNA delivery and activates natural killer T cells for superior tumor immunotherapy

Lipid nanoparticles (LNPs) have emerged as a clinically validated platform for cancer immunotherapy; however, challenges remain in optimizing RNA delivery and promoting synergistic immune activation. To address these issues, we developed a modified LNP system that incorporates α-galactosylceramide (α-GalCer), a CD1d-binding glycolipid known to activate invariant natural killer T (iNKT) cells.

Through structural optimization, we created the α-GalCer-LNP (G-LNP), which offers three primary advantages over conventional four-component LNPs: (1) enhanced mRNA transfection efficiency due to improved endosomal/lysosomal escape, (2) increased capacity for in vivo DC transfection, leading to robust activation of tumor-specific CD8+ T cells via MHC-I and iNKT cells via the CD1d pathway, and (3) reprogramming of the tumor microenvironment, resulting in a 1.5-fold increase in iNKT cell infiltration and sustained elevation of IFN-γ (>24 h) in lymph nodes. In a TC-1 cervical carcinoma model, G-LNP induced complete tumor regression in 100 % of treated mice (compared to 42.85 % for standard LNP) and provided long-term protection against tumor rechallenge (lasting >100 days).

Mechanistic studies showed that G-LNP preferentially targets CD11c+ DC in the lymph nodes, facilitating coordinated antigen presentation and innate immune activation. This five-component engineering strategy establishes a versatile platform to enhance the functionality of LNPs for the development of next-generation cancer vaccines.”

Title: α-GalCer-LNP ehanced mRNA delivery and activates natural killer T cells for superior tumor immunotherapy

Authors: Kexin Zhang, Zhen Xu, Zexiu Xiao, Fei Cao, Jing Wang, Yuandong Xu, Winson M.J. Ma, Sihui Long, Gao-Feng Zha

Read the Full Article.

Hung Trinh

More posts featuring Hung Trinh.

cancer cancer immunotherapy cancer vaccines Fei Cao Gao-Feng Zha Hung Trinh Jing Wang Kexin Zhang OncoDaily Oncology Sihui Long Winson M.J. Ma Yuandong Xu Zexiu Xiao Zhen Xu

New Paper Alert: Breakthrough iNKT Cell Therapy Achieves Complete Remission in Metastatic Germ Cell Tumor

"God Invented This" - Pat Soon-Shiong on Cancer Discovery

Yüksel Ürün: Science Is Better When It’s Shared

Oliver Bogler: Grant Tips

Marty Makary: FDA Has Published More than 200 Complete Response Letters